Hematologic in a sentence | Use of the word hematologic examples

It can also be a presenting sign of a plethora of cancers (hey, you asked for the worst news) including lymphomas, leukemia, and other hematologic disorders and blood-based cancers.

April 28 (Reuters) – PZ Cormay SA: * Said on Thursday that in the course of discussions concerning changing a cooperation formula, Diagdev SAS renounced a cooperation with company’s unit Orphée SA which was signed in 2015 and concerned creation of a new 3-DIFF hematologic analyzer * Diagdev SAS expressed a will to negotiate the rules of terminating the cooperation Source text for Eikon: Further company coverage: (Gdynia Newsroom)

The European Commission said on Monday the probe will focus on niche medicines containing the active pharmaceutical ingredients chlorambucil, melphalan, mercaptopurine, tioguanine and busulfan for treating cancer such as hematologic tumours.

Treatment with Takeda’s Ninlaro, in combination with dexamethasone, did not show a significant improvement in patients’ overall hematologic response compared to standard of care regimens, the company said.

My mom, just the kind of mother she is, she was my rock, she was my support system doing all the worrying and all the praying and it felt like I was a little bit on an island.” Admitting that he was scared, Reigns calls the time period “pretty shocking.” He explains, “It was a crazy transition to be a young man at 21, 22 with all the responsibilities being thrown on my shoulders.” Thankfully, Reigns cancer went into hematologic remission — a normal, complete blood cell count — about a year and a half after he was first diagnosed.

March 30 (Reuters) – Cellectar Biosciences Inc: * After much anticipation, Cellectar Biosciences initiates NCI-supported phase ii trial of CLR 131 in multiple myeloma and other blood cancers * Cellectar Biosciences-study will be conducted in up to 15 centers in U.S. for patients with variety of orphan-designated relapse or refractory hematologic cancers * Cellectar Biosciences Inc – Cellectar will receive approximately $2 million in a non-dilutive grant to help fund trial from national cancer institute * Cellectar Biosciences Inc – initial efficacy data from study expected as early as second half of 2017 Source text for Eikon: Further company coverage:

The EU competition enforcer said the probe will focus on niche medicines containing the active pharmaceutical ingredients chlorambucil, melphalan, mercaptopurine, tioguanine and busulfan for treating cancer such as hematologic tumors.

The cost of guidelines Prasad and his colleagues created a dataset of 47 drugs approved for marketing by the FDA for adult hematologic or solid cancers between 2011 and 2015.

It is designed to home in on an antigen, or a foreign substance, in Hodgkin’s lymphoma and in several types of T-cell lymphoma and other hematologic malignancies.

But there’s a ‘catch’ “When there’s an impact on overall survival, it’s always notable,” said Dr. Nelson Chao, chief of the Division of hematologic Malignancies and Cellular Therapy at the Duke University School of Medicine.

Treatment with Takeda’s Ninlaro, in combination with dexamethasone, did not show a significant improvement in patients’ overall hematologic response compared to standard of care regimens, the company said.

Dec 5 (Reuters) – Celgene Corp * patients with MDS, CMML or AML who were relapsed or refractory to prior HMA therapies and who received CC-486 had a 38% overall response rate * Combined analysis of oral epigenetic therapy, demonstrated hematologic responses in patients who received prior epigenetic hypo-methylating agents Source text for Eikon: Further company coverage:

Sept 7 (Reuters) – Iovance Biotherapeutics Inc * Iovance Biotherapeutics enters into a research collaboration focused on hematologic malignancies with the Ohio State University Comprehensive Cancer Center * ‍Collaboration will initially focus on hematologic malignancies in areas of poor prognostic cancers​ Source text for Eikon: Further company coverage:

July 13 (Reuters) – Immune Pharmaceuticals Inc: * Immune Pharmaceuticals announces filing of a patent protecting use of ceplene (histamine dihydrochloride) in hematologic cancers * Immune Pharmaceuticals Inc – ‍patent aims to protect use of ceplene in forms of cancer where malignant cells may harbor a mutated oncogene, NPM1​ Source text for Eikon: Further company coverage:

May 2 (Reuters) – Kura Oncology Inc: * KURA ONCOLOGY ANNOUNCES NEW PATENT FOR TIPIFARNIB IN hematologic MALIGNANCIES * KURA ONCOLOGY INC – BIOMARKER-ENRICHED DATA FROM ONGOING PHASE 2 TRIALS OF TIPIFARNIB IN hematologic MALIGNANCIES EXPECTED IN H2 OF 2018 * KURA ONCOLOGY INC – PATENT EXPANDS PROTECTION FOR TIPIFARNIB IN U.S., PROVIDES EXCLUSIVITY IN CERTAIN CXCL12-EXPRESSING CANCERS TO 2037 Source text for Eikon: Further company coverage:

Jan 8 (Reuters) – Agios Pharmaceuticals Inc: * AGIOS OUTLINES KEY 2018 PRIORITIES EXPANDING CLINICAL AND RESEARCH PROGRAMS TO DRIVE LONG TERM VALUE * AGIOS PHARMACEUTICALS INC – SEVENTH IND SUBMISSION FOR A DHODH INHIBITOR FOR TREATMENT OF hematologic MALIGNANCIES EXPECTED IN 4Q 2018 * AGIOS – 2017 YEAR END CASH, CASH EQUIVALENTS & MARKETABLE SECURITIES OF $568M FUNDS EXPANDED CLINICAL & RESEARCH PROGRAMS THROUGH END OF 3Q 2019 * AGIOS PHARMACEUTICALS INC – TWO PIVOTAL TRIALS IN PYRUVATE KINASE DEFICIENCY WITH AG-348, ACTIVATE-T TO INITIATE IN 1Q 2018 AND ACTIVATE IN 2Q 2018 * AGIOS PHARMACEUTICALS INC – PHASE 2 PROOF OF CONCEPT TRIAL OF AG-348 IN THALASSEMIA PLANNED FOR 4Q 2018 * AGIOS PHARMACEUTICALS INC – MAT2A INHIBITOR AG-270 EXPECTED TO ENTER PHASE 1 DOSE-ESCALATION TRIAL IN MTAP-DELETED TUMORS IN 1Q 2018 Source text for Eikon: Further company coverage:

July 11 (Reuters) – Pluristem Therapeutics Inc : * Pluristem advances its U.S. FDA trial in hematologic indication * Trial received clearance from U.S. Food and Drug Administration earlier this year and enrollment is planned to begin in coming months Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Sept 12 (Reuters) – Xencor Inc * Oncology bispecific program XmAb14045 for the treatment of acute myeloid leukemia and other CD123-expressing hematologic malignancies * Says expects to advance additional candidates using Xencor’s XmAb bispecific technology into clinic by end of 2017 Source text for Eikon: Further company coverage:

Nov 15 (Reuters) – Trillium Therapeutics Inc- * Trillium announces private placement * Trillium Therapeutics – ‍entered into subscription agreements for sale of 1.95 million shares & 400,000 Series II non-voting convertible first preferred shares​ * Trillium Therapeutics – ‍net proceeds from private placement will be used to continue development of TTI-621 in hematologic cancers and solid tumors​ * Trillium Therapeutics Inc – ‍subscription agreements for offering at a price of U.S.$8.50 per share Source text for Eikon: Further company coverage:

Aug 8 (Reuters) – MEI Pharma Inc * Helsinn Group and Mei Pharma enter strategic agreement for the development and commercialization of pracinostat for the treatment of acute myeloid leukemia and other hematologic diseases * To receive $20 million in near-term cash payments, plus up to $444 million in potential milestone payments as well as royalties on future sales * Helsinn, co to collaborate to explore optimal dosing regimen of pracinostat in combination with azacitidine for treatment of high-risk mds * Agreement enables Helsinn to expand into oncology therapeutics with new phase iii-ready asset Source text for Eikon: Further company coverage:

June 20 (Reuters) – Novimmune SA IPO-NOVI.S: * TG THERAPEUTICS AND NOVIMMUNE SA ANNOUNCE GLOBAL AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF A NOVEL ANTI-CD47/ ANTI-CD19 BISPECIFIC ANTIBODY * TG THERAPEUTICS INC – COMPANIES WILL JOINTLY DEVELOP PRODUCT ON A WORLDWIDE BASIS, FOCUSING ON INDICATIONS IN AREA OF hematologic B-CELL MALIGNANCIES * TG THERAPEUTICS – CLINICAL TRIALS ON TG-1801 ARE EXPECTED TO COMMENCE LATER THIS YEAR OR EARLY IN 2019 * TG THERAPEUTICS – TO MAKE UP-FRONT & MILESTONES PAYMENTS BASED ON EARLY CLINICAL DEVELOPMENT * TG THERAPEUTICS – TO BE RESPONSIBLE FOR COSTS OF CLINICAL DEVELOPMENT OF PRODUCTS THROUGH END OF PHASE II Source text for Eikon: Further company coverage:

Of 125 patients available for evaluation in the expansion of a Phase I study, 30.4 percent experienced a complete response or a complete response with partial hematologic recovery (CRh), researchers reported.

Cambridge, Massachusetts-based Biogen focuses on discovering and developing therapies for neurological and hematologic disorders including multiple sclerosis and hemophilia.

As part of our ongoing efforts to improve the health of children with SCD and hematologic disorders, our team actively participates in and leads investigator-initiated research studies and multi-institutional clinical trials on a regional and national basis.

Mr. Pierce (left), 36, is a senior director, overseeing the global commercial department for hematologic malignancy therapies, at Pfizer Oncology in New York, a unit of Pfizer, the pharmaceutical company.

“I asked myself, ‘Who is this beautiful woman?’” said Dr. Koehne, who then worked in the adult bone marrow transplantation service of the Division of hematologic Oncology at Memorial Sloan Kettering Cancer Center in New York.

We don’t argue.” On July 25, 2017, while Ms. DeMaria was cooking dinner in Vero Beach, Dr. Koehne, who was about to start his new position as the chief of bone marrow transplantation and hematologic oncology at the Miami Cancer Institute, grabbed the ring he had made for her, hid it behind his back and dropped to one knee.

But leukemia, similar to other hematologic malignancies, is not a cancer for which surgery is a useful therapy, since its source, the bone marrow, can’t be removed with a scalpel.

“The good news is that all of them are alive,” said Dr. Edward A. Stadtmauer, the section chief of hematologic malignancies at the University of Pennsylvania Abramson Cancer Center.

Dec 9(Reuters) – ARGENX SE: * ARGENX ANNOUNCED ON SATURDAY RECEIPT OF FIRST MILESTONE PAYMENT UNDER JANSSEN COLLABORATION AND PROVIDES DATA UPDATE FROM PHASE 1 DOSE ESCALATION TRIAL OF CUSATUZUMAB IN ACUTE MYELOID LEUKEMIA AT ASH ANNUAL MEETING * COMPANY WILL RECEIVE FIRST DEVELOPMENT MILESTONE PAYMENT OF $25 MILLION FROM GLOBAL COLLABORATION AND LICENSE AGREEMENT WITH CILAG GMBH INTERNATIONAL, AFFILIATE OF JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON * KEY HIGHLIGHTS FROM ASH: 100% OF PATIENTS ACHIEVED RESPONSE INCLUDING EIGHT WITH COMPLETE RESPONSE (CR), TWO WITH COMPLETE RESPONSE WITH INCOMPLETE hematologic RECOVERY (CRI), AND TWO WITH PARTIAL RESPONSE (PR); 83% OF PATIENTS ACHIEVED EITHER A CR OR CRI * KEY HIGHLIGHTS FROM ASH: OF NINE CR/CRI PATIENTS EVALUABLE FOR MINIMAL RESIDUAL DISEASE (MRD) NEGATIVITY, FOUR ACHIEVED MRD NEGATIVITY USING THRESHOLD OF 10-3 WHICH IS CONSISTENT WITH PREVIOUS DATA CUT-OFF IN OCTOBER 2018 * KEY HIGHLIGHTS FROM ASH: FOUR PATIENTS HAVE REMAINED IN STUDY FOR AT LEAST 12 MONTHS * KEY HIGHLIGHTS FROM ASH: THREE PATIENTS FROM STUDY HAVE BEEN RE-CLASSIFIED WITH RISK CATEGORY BASED ON NEW MUTATION INFORMATION OR REASSESSMENT OF EXISTING MUTATION INFORMATION * CUSATUZUMAB CONTINUED TO BE WELL-TOLERATED IN PATIENTS WITH AML ACROSS THE DIFFERENT DOSES Source text: bit.ly/2Ru8txU Further company coverage: (Gdansk Newsroom)

“We have to take each method one by one and talk about the safety, the benefits, the risks of each one and really go through what science we have — it’s not perfect, but we have quite a bit of safety evidence.” In addition, girls with bleeding disorders may need hematologic medications, and anyone who is anemic will need iron.

* PLANS TO INITIATE PHASE I STUDY OF MDG1021 IN PATIENTS WITH RELAPSED OR PERSISTENT hematologic MALIGNANCIES AFTER ALLO-HSCT IN FIRST HALF OF 2020.

We hope hematologic in a sentence examples were helpful.